Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

Gaetano Santulli

doi:10.1056/NEJMc2114590

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

Gaetano Santulli

Medicine

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	e17
Journal	The New England journal of medicine
Volume	386
Issue number	7
DOIs	https://doi.org/10.1056/NEJMc2114590
State	Published - Feb 17 2022

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc2114590

Cite this

@article{d3af77d22c26446c83ddd0a67b479e02,

title = "Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes",

author = "Gaetano Santulli",

year = "2022",

month = feb,

day = "17",

doi = "10.1056/NEJMc2114590",

language = "English (US)",

volume = "386",

pages = "e17",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "7",

}

TY - JOUR

T1 - Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

AU - Santulli, Gaetano

PY - 2022/2/17

Y1 - 2022/2/17

UR - http://www.scopus.com/inward/record.url?scp=85124779186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124779186&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2114590

DO - 10.1056/NEJMc2114590

M3 - Letter

C2 - 35172066

AN - SCOPUS:85124779186

SN - 0028-4793

VL - 386

SP - e17

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 7

ER -

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this